Abstract
Aims: Central nervous system lymphoma (CNSL) is a rare and aggressive subtype of extranodal non-Hodgkin lymphoma, including primary and secondary forms. Despite advances in treatment, outcomes remain suboptimal. In this study, real-world treatment outcomes and prognostic factors in CNSL patients were evaluated. Methods: The study should be described, including selection criteria, design (randomized, retrospective/prospective, etc.), and statistical methods applied, if applicable. Results: The median age was 53 years, and 62.5% of patients had primary CNSL. High-dose methotrexate-based regimens yielded high response rates, with overall response rates of 92.3% for the MATRix regimen and 86.7% for the modified Bonn protocol. Autologous stem cell transplantation (ASCT) was associated with an improvement in complete/unconfirmed complete response rates (52.5% pre-ASCT vs. 65% post-ASCT). At a median follow-up of 1124 days, the overall survival and progression-free survival rates were 52.5% and 35%, respectively. Relapse occurred in 50% of patients. Prognostic scoring systems demonstrated limited applicability due to missing data and the small sample size. Conclusion: High-dose methotrexate-based regimens followed by ASCT remain effective in CNSL; however, relapse rates remain high. Improved prognostic models and novel therapies are needed.